Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyglucosamine L112 is an indigestible dietary fiber derived from the chitin shells of crustaceans. It acts as a lipid adsorbent in the gastrointestinal tract by binding to dietary fats and cholesterol through ionic and lipophilic interactions. This physical binding forms a gel structure that reduces the absorption of fats and cholesterol in the small intestine. The primary indications are for weight reduction, weight management, and lowering LDL cholesterol levels in adults with a body mass index (BMI) of 25 or higher. Polyglucosamine L112 is used as part of a reduced-calorie diet to support treatment of overweight and obesity. Its mechanism is purely physical—no pharmacological or metabolic action occurs—and it has been shown in clinical studies to result in significant weight loss compared to placebo when combined with caloric restriction[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyglucosamine l112.